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Abstract: Robust assay development for SARS-CoV-2 serological testing requires assessment of
asymptomatic and non-hospitalised individuals to determine if assays are sensitive to mild antibody
responses. Our study evaluated the performance characteristics of two high-throughput SARS-
CoV-2 IgG nucleocapsid assays (Abbott Architect and Roche) and The Binding Site (TBS) Anti-
Spike IgG/A/M ELISA kit in samples from healthcare workers (HCWs). The 252 samples were
collected from multi-site NHS trusts and analysed for SARS-CoV-2 serology. Assay performance was
evaluated between these three platforms and ROC curves were used to redefine the Abbott threshold.
Concordance between Abbott and TBS was 66%. Any discrepant results were analysed using Roche,
which showed 100% concordance with TBS. Analysis conducted in HCWs within 58 days post-PCR
result demonstrated 100% sensitivity for both Abbott and Roche. Longitudinal analysis for >100 days
post-PCR led to sensitivity of 77.2% and 100% for Abbott and Roche, respectively. A redefined Abbott
threshold (0.64) increased sensitivity to 90%, producing results comparable to TBS and Roche. The
manufacturer’s threshold set by Abbott contributes to lower sensitivity and elevated false-negative
occurrences. Abbott performance improved upon re-optimisation of the cut-off threshold. Our
findings provided evidence that TBS can be used as bespoke alternative for SARS-CoV-2 serology
analysis where high-throughput platforms are not feasible on site.
Keywords: SARS-CoV-2; Roche Elecsys SARS-CoV-2 antibody assay; Abbott IgG antibody assay;
The Binding Site total antibody assay
1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible
for coronavirus disease 2019 (COVID-19), has led to a global pandemic with more than
183 million confirmed infections and 3.9 million fatalities [1]. Since the initial identification
of COVID-19, mass testing and case determination have been a mainstay strategy for
controlling viral transmission and guiding both the public health and political strategies
required to mitigate the deleterious consequences of SARS-CoV-2.
SARS-CoV-2 testing is represented by the initial detection of the virus in nasopha-
ryngeal specimens by real-time polymerase chain reaction (RT-PCR), which is currently
considered as the gold standard for confirming suspected diagnosis and identifying asymp-
tomatic carriers [2]. Complementing RT-PCR investigation is serological testing, which
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utilises immunoassays for the detection of SARS-CoV-2 antibodies as a measure of the
adaptive immune response to natural infection and/or vaccines. Immunoassays either
detect specific antibody types (such as immunoglobulin M or immunoglobulin G) or the
total antibody. However, antibody detection usually occurs 5–7 days post-infection; thus, it
is not representative of acute infection [3]. Whilst the degree and duration of immunity
conferred by these antibodies are currently unclear, the widescale use of serological testing
has been applied at the population level to establish population exposure. Other uses of
serological analysis include assessing the individual infection risk and measuring humoral
immunity elicited in vaccine trials [4].
In response, several immunoassays have been designed by manufacturers to meet
global laboratory infrastructures, enabling high-throughput serological analysis. Two of
the earliest tests to become commercially available both measured IgG antibodies against
the SARS-CoV-2 nucleocapsid protein. The Abbott SARS-CoV-2 IgG assay was initially
validated on sera taken from hospitalised COVID-19 patients at ≥14 days post RT-PCR
(n = 31) and 997 pre-pandemic sera, and reported a sensitivity and specificity of 100% (95%
CI: 95.89–100.00) and 99.6% (95% CI: 98.98–99.89), respectively [5]. The Roche Elecsys Anti-
SARS-CoV-2 assay was initially validated using sera from COVID-19 patients at ≥14 days
post RT-PCR (n = 102) and 10,453 pre-pandemic sera, and reported a sensitivity and
specificity of 99.5% (95% CI: 97.0–100%) and 99.80% (95% CI: 99.69–99.88%), respectively [6].
The majority of reports on the performance of serological assays have been performed
on samples from hospitalised patients with severe COVID-19, who have a high viral load
and elicit robust immune responses, which may in part account for the high sensitivities
reported. To date, there are limited studies that have focused on evaluating assay perfor-
mance in non-hospitalised or community-based COVID-19 cases. From the limited data
available in such patients, studies have demonstrated the poor sensitivity of the Abbott
assay in the detection of low levels of antibodies. For instance, a pre-print report high-
lighted a sensitivity of just 61.5% when investigating community-based COVID-19 cases
(n = 26) [7].
Understanding antibody responses in asymptomatic and non-hospitalised individuals
is of major importance for ascertaining viral transmission and for SARS-CoV-2 serological
assay development [8]. As a result, it is crucial that antibody assays are able to detect low
levels of antibodies in order to be of use in both clinical and sero-epidemiological settings.
The Binding Site (TBS) Anti-IgG/A/M SARS-CoV-2 ELISA (TBS, Birmingham, UK) mea-
sures IgG, IgA, and IgM antibodies against the SARS-CoV-2 trimeric spike glycoprotein,
and has been shown to detect antibodies in PCR-confirmed non-hospitalised asymptomatic
COVID-19 patients and patients with mild disease [9].
To date, limited direct assessments of multiple immunoassays have been conducted on
large data sets from non-hospitalised patients. We therefore sought to evaluate the Abbott,
Roche, and TBS immunoassays in samples taken from healthcare workers to identify assay
sensitivities and redefine the assay thresholds required for optimisation.
2. Methods
2.1. Patients and Study Design
The urgent need to better understand SARS-CoV-2 seroprevalence during the first
wave of the pandemic led to regulatory bodies, such as the Food and Drug Administration
(FDA) and the Medicines and Healthcare products Regulatory agency (MHRA), to approve
the Abbott Architect nucleocapsid (NC) IgG assay (hereon referred to as Abbott) [Abbott,
Chicago, IL, USA] and Elecsys® Anti-SARS-CoV-2 IgG nucleocapsid immunoassays [Roche,
Basel, Switzerland]. In the UK, these were rolled out as generic assays, as part of a wider
national screening programme to determine seroprevalence in healthcare workers and to
determine prior SARS-CoV-2 exposure in clinical settings. The mandatory and fast-tracked
deployment of such assays meant that health institutions and requestors did not have
access to extensive assay performance characteristics to make informed choices.
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This study was conducted at a time when no licensed SARS-CoV-2 vaccines were
available; therefore, positive antibody responses correlated with natural infection. It is well
known that following SARS-CoV-2 infection, humoral responses elicit an early response
against both the NC and spike proteins [10]. Such a polyclonal response demonstrates a
flexibility of antigen choice, spike or NC, in immunoassays, as natural infection should
stimulate the humoral response to multiple SARS-CoV-2 structural sites. Therefore, we
compared and evaluated serological outcomes between two high-throughput immunoas-
says, Abbott and Roche, alongside The Binding Site (TBS) human anti-spike IgG/A/M
SARS-CoV-2 ELISA [The Binding Site, Birmingham, UK].
A comparative evaluation of the above immunoassays was conducted at two different
sites: Queen Alexandra Hospital, Portsmouth Hospitals University NHS Trust (PHU),
and the Dudley Group of Hospitals NHS Foundation Trust (DGH). At PHU, this study
was approved by Portsmouth Hospital NHS Trust Research Ethics Committee. Serum
samples (n = 188) were collected that had been provided as part of the SIREN research
study (Clinicaltrials.gov identifier: NCT12345678). Healthcare workers aged 18 years or
older provided fortnightly blood samples for SARS-CoV-2 serology surveillance. Only five
participants had a positive SARS-CoV-2 RT-PCR prior to SIREN enrolment. At DGH, serum
from healthcare workers (n = 64), aged 18 years or older, was collected; 39 samples were
confirmed RT-PCR-positive for SARS-CoV-2 and 9 were RT-PCR-negative and symptom-
negative for SARS-CoV-2 [11].
2.2. Anti-SARS-CoV-2 Assays
Samples from PHU were initially analysed for SARS-CoV-2 antibodies at the Depart-
ment of Medical Microbiology, PHU, using the Abbott nucleocapsid IgG assay [Abbott,
Chicago, IL, USA] as part of the SIREN study. Samples were identified as positive or nega-
tive based on the manufacturer’s cut-off (Supplementary Data, Table S1). Samples were
further evaluated using The Binding Site (TBS) human anti-IgG/A/M SARS-CoV-2 ELISA
[The Binding Site, Birmingham, UK]. If discordance was reported between the TBS and
Abbott platforms, the samples were evaluated using the Elecsys® Anti-SARS-CoV-2 IgG
nucleocapsid immunoassay [Roche, Basel, Switzerland] at Poole NHS Trust. Samples from
DGH were analysed using the Abbott nucleocapsid IgG assay [Abbott, Chicago, IL, USA]
and further evaluated using the Elecsys Anti-SARS-CoV-2 IgG nucleocapsid immunoassay
[Roche, Basel, Switzerland]. Assays were conducted in accordance with the manufacturers’
standard operating procedures by HCPC-registered laboratory staff in laboratories that
held United Kingdom Accreditation Service accreditation. All assays were conducted with
specified controls and calibrants using clinical cut-off thresholds for negative and positive
as determined by the manufacturers.
2.3. Procedures
Primary serum separator tubes were stored at 2–8 ◦C for up to seven days after
venepuncture. Selected samples for each run were derived within this seven day period
and primary samples were centrifuged for 10 min at 3500× g. Supernatant (0.5–1 mL)
was derived and made up into sample aliquots, which were stored at −20 ◦C until they
were processed by the respective immunoassay. Samples were limited to fewer than three
freeze-thaw cycles.
2.4. Statistical Analysis
Analyses were performed using Graphpad Prism v9.0.1 (La Jolla, CA, USA) and SPSS
v27.0 (IBM Corp, Armonk, NY, USA). Fisher’s exact test was used to evaluate categor-
ical data between immunoassays, whereas Chi-squared analysis was used to evaluate
categorical data as a three-way comparison method. One-sample t-test was employed to
determine the significance of result outcomes produced by each immunoassay. Sensitivity
and specificity with exact binomial 95% CI for assays was carried out by Fisher’s exact test.
Assessment of agreement between immunoassays was conducted by concordance (percent-
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age) and by Î-Cohen. Receiver operator characteristic (ROC) curves defined trade-offs in
assay sensitivity and specificity for Abbott immunoassay.
2.5. Ethical Considerations
This study was conducted based on service evaluation, which did not require eth-
ical approval. Samples were derived from altruistic healthcare volunteers and were de-
signed for assay verification. All samples were derived after informed consent was gained
from volunteers.
3. Results
3.1. PHU Study: Comparison between Abbott and TBS
Comparing antibody levels using the Abbott and TBS assays in 188 serum samples
taken from healthcare workers (HCWs) found concordant results in 125 samples (66.4%,
Figure 1A), demonstrating a fair agreement between assays as measured using Î-Cohen
(Î= 0.377, 95% CI: 0.27–0.48, SE = 0.054). A two-fold decrease in positive antibody detection
was seen with the Abbott assay compared to TBS, demonstrating a significant difference
in outcomes between assays (Fisher’s exact test, p < 0.0001). Of the samples reported as
negative using the Abbott assay (n = 131), 59 were reported as positive using the TBS assay
(p < 0.0001, Figure 1B). As seen in Figure 1B, a clear demarcation of positive and negative
samples can be seen using the TBS assay. In these 59 samples, the results from the Abbott
assays fell within the index values of 0.26–1.31 (Figure 1C).
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Figure 1. Comparative evaluation between Abbott and TBS, which detect antibody responses against SARS-CoV-2 nucle-
ocapsid and spike, respectively. Results are presented as (A) bar graph, which compares positive and negative SARS-CoV-
2 antibody outcomes in 188 samples analysed between Abbott and TBS. Statistically significant differences for positive 
versus negative outcomes derived from both assays (**** = p < 0.0001, Fisher’s exact test). Nested scatterplot is presented 
by (B), which portrays the difference in outcomes produced by TBS in analysis of 131 samples deemed negative by Abbott 
(green dashed line = cut-off for Abbott (1.40 index value)). Of TBS outcomes, 45% were positive (red dashed line = cut-off 
for TBS (1.0 index value)) and above TBS mean index value (1.06, 95% CI: 0.92–1.20), which was significantly higher com-
pared to TBS (0.36 index value, 95% CI: 0.31–0.46, **** = p < 0.0001, one sample t-test). Paired index values derived from 
negative sample analysis, from Abbott and TBS, are presented on the scatterplot in (C). Discrepant results from Abbott 
(blue dots) are categorised within the brown rectangular box (n = 59, index values; 0.26–1.31), where reciprocal analysis 
by TBS (grey triangles) was deemed positive in all 59 samples. The x-axis represents sample identity (S1 = sample 1) de-
rived from individuals for analysis in Abbott and TBS. 
Figure 1. Comparative evaluation between Abbott and TBS, which detect antibody responses against SARS-CoV-2 nucleocapsid
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and spike, respectively. Results are presented as (A) bar graph, which compares positive and negative SARS-CoV-2 antibody
outcomes in 188 samples analysed between Abbott and TBS. Statistically significant differences for positive versus negative
outcomes derived from both assays (**** = p < 0.0001, Fisher’s exact test). Nested scatterplot is presented by (B), which
portrays the difference in outcomes produced by TBS in analysis of 131 samples deemed negative by Abbott (green dashed
line = cut-off for Abbott (1.40 index value)). Of TBS outcomes, 45% were positive (red dashed line = cut-off for TBS (1.0
index value)) and above TBS mean index value (1.06, 95% CI: 0.92–1.20), which was significantly higher compared to
TBS (0.36 index value, 95% CI: 0.31–0.46, **** = p < 0.0001, one sample t-test). Paired index values derived from negative
sample analysis, from Abbott and TBS, are presented on the scatterplot in (C). Discrepant results from Abbott (blue dots)
are categorised within the brown rectangular box (n = 59, index values; 0.26–1.31), where reciprocal analysis by TBS (grey
triangles) was deemed positive in all 59 samples. The x-axis represents sample identity (S1 = sample 1) derived from
individuals for analysis in Abbott and TBS.
Of these 59 discordant samples between Abbott and TBS analysis, 48 samples were
sent to Poole NHS Trust for analysis using the Roche Elecsys Anti-SARS-CoV-2 IgG nu-
cleocapsid assay. Only one sample result (1/48) was in concordance between Roche and
Abbott, demonstrating poor agreement (Î-Cohen= −0.133, 95% CI: −0.26–0.02). whereas
all 48 samples analysed using Roche produced outcomes that were 100% in agreement
with results generated from TBS. Comparative analysis of 48 samples across the three im-
munoassays demonstrated that Abbott reported negative outcomes in 45 samples, whereas
negative outcomes were only observed in 4 samples from TBS and Roche. Overall, a
significant difference in outcomes was generated by Abbott in comparison to Roche and
TBS immunoassays (Chi-square, p < 0.0001, Figure 2).





Figure 2. Three-way method comparison between Abbott, TBS, and Roche. Bar graph portrays 
SARS-CoV-2 antibody outcomes produced by Roche in the discordant sample set (n = 48) between 
Abbott and TBS. Statistically significant differences observed from outcomes generated by Abbott 
versus Roche and TBS (**** = p < 0.0001, Chi-square test). Outcomes produced by both TBS and 
Roche are identical to each other (100% concordance). 
3.2. DGH Study: Evaluation of Sensitivity and Specificity between Roche and Abbott  
Serum samples were collected from 48 healthcare workers (HCWs) within 58 days of 
registering a RT-PCR result or the onset of COVID-19 symptoms (PCR positive: 39, PCR 
negative: 9). Further, 16 samples were collected from HCWs where RT-PCR analysis was 
not performed and showed no signs and symptoms of COVID-19 infection; these were 
classified as presumed COVID-19 negatives. Amongst these samples, 28 were followed 
for >100 days post-PCR result or symptom onset (PCR-positive: 22, PCR-negative: 6).  
In samples analysed within ≥19–≤58 days, the Abbott and Roche assays showed 100% 
concordance and perfect agreement (ƙ-Cohen: 1.000). All assay characteristics for both the 
Roche and Abbott assays were identical (Table 1); both assays reported sensitivity and 
specificity of 97.4% and 80%, respectively, with an LR of 4.87.  
Samples analysed after >100 days showed a concordance of 79% (22/28) with a mod-
erate agreement (ƙ-Cohen: 0.462, 95% CI: 0.15–0.78). Of the six discordant samples, which 
were reported as negative using the Abbott assay, was shown to be positive using the 
Roche assay. Of these, 5/6 were PCR-positive at initial testing, and the sample that was 
PCR-negative tested positive in both assays at the earlier timepoint.  
Table 1. Assay performance characteristics of Roche and Abbott in analysis of HCWs samples both 
within 58 days and >100 days of PCR result or symptom onset. Specificity was assessed using PCR-
negative or no-onset of COVID-19 symptoms samples and sensitivity was assessed using RT-PCR 
positive samples. CI = Confidence interval. SE = Standard error. 
Parameter 
Within 58 Days Post-
PCR/Symptom Onset 
>100 Days Post-PCR/Symptom 
Onset 
Abbott Roche Abbott Roche 
Sensitivity  97.4% (95% CI: 86.8–99.8%) 
77.3% (95% CI: 
56.6–89.9%) 
100% (95% CI: 
85.1–100%) 
Specificity 80.0% (95% CI: 60.9– 91.1%) 83.3% (95% CI: 43.7–99.2%) 
Figure 2. Three-way method comparison between Abbott, TBS, and Roche. Bar graph portrays
SARS-CoV-2 antibody outcomes produced by Roche in the discordant sample set (n = 48) between
Abbott and TBS. Statistically significant differences observed from outcomes generated by Abbott
versus Roche and TBS (**** = p < 0.0001, Chi-square test). Outcomes produced by both TBS and
Roche are identical to each other (100% concordance).
3.2. DGH Study: Evaluation of Sensitivity and Specificity between Roche and Abbott
Serum samples were collected from 48 healthcare workers (HCWs) within 58 days of
registering a RT-PCR result or the onset of COVID-19 symptoms (PCR positive: 39, PCR
negative: 9). Further, 16 samples were collected from HCWs where RT-PCR analysis was
not performed and showed no signs and symptoms of COVID-19 infection; these were
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classified as presumed COVID-19 negatives. Amongst these samples, 28 were followed for
>100 days post-PCR result or symptom onset (PCR-positive: 22, PCR-negative: 6).
In samples analysed within ≥19–≤58 days, the Abbott and Roche assays showed
100% concordance and perfect agreement (Î-Cohen: 1.000). All assay characteristics for
both the Roche and Abbott assays were identical (Table 1); both assays reported sensitivity
and specificity of 97.4% and 80%, respectively, with an LR of 4.87.
Table 1. Assay performance characteristics of Roche and Abbott in analysis of HCWs samples both within 58 days and
>100 days of PCR result or symptom onset. Specificity was assessed using PCR-negative or no-onset of COVID-19 symptoms
samples and sensitivity was assessed using RT-PCR positive samples. CI = Confidence interval. SE = Standard error.
Parameter
Within 58 Days Post-PCR/Symptom Onset >100 Days Post-PCR/Symptom Onset
Abbott Roche Abbott Roche
Sensitivity 97.4% (95% CI: 86.8–99.8%) 77.3% (95% CI: 56.6–89.9%) 100% (95% CI: 85.1–100%)
Specificity 80.0% (95% CI: 60.9– 91.1%) 83.3% (95% CI: 43.7–99.2%)
PPV 0.88 (95% CI: 0.75–0.95) 0.94 (95% CI: 0.74–0.99) 0.96 (95% CI: 0.79–0.99)
NPV 0.95 (95% CI: 0.77–0.99) 0.50 (95% CI: 0.24–0.76) 1.00 (0.57–1.00)
LR 4.87 4.64 6.00
Î-Cohen 1.000 SE: 0.000 0.462 SE: 0.164
Samples analysed after >100 days showed a concordance of 79% (22/28) with a
moderate agreement (Î-Cohen: 0.462, 95% CI: 0.15–0.78). Of the six discordant samples,
which were reported as negative using the Abbott assay, was shown to be positive using
the Roche assay. Of these, 5/6 were PCR-positive at initial testing, and the sample that was
PCR-negative tested positive in both assays at the earlier timepoint.
3.3. DGH Abbott–Roche Comparison Consistent with PHU Study Discordant Range
To further interrogate the assay performance, the samples for which low positive
results were recorded (n = 20, range: 1.28–4.00 index value) using the Roche assay were
compared to the result generated using the Abbott assay (Figure 3). Concordance was found
in only 4/20 samples (20%). Consistent with the findings from PHU, most discrepancies
arose in samples that had a result between 0.26–1.31 according to the Abbott assay. This
further exemplified the inferior sensitivity of the Abbott assay, which gave significantly
more false negatives (Fisher’s exact test, p < 0.0001) in comparison to the Roche assay.
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Figure 3. Roche-reported low-level positive samples analysed by Abbott. Statistically significant
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difference in reported outcomes observed in low-level positive samples analysed by Abbott. All
discordant outcomes (n = 16) reported by Abbott were below the manufacturer’s set threshold (brown
dashed line) and comprised index values of 0.26–1.31, consistent with PHU Abbott versus TBS
discordant range. Black dashed line = Roche manufacturer threshold. Brown dashed line = Abbott
manufacture threshold.
3.4. Definition of Thresholds Harmonising Abbott, TBS, and Roche Results
The above analyses allowed us to define the optimal threshold enabling concordance
and agreement between the three assays (Figure 4). Based on the ROC analysis, a new
threshold of ≥0.64 for the index value of the Abbott assay was selected. Using the ROC
curve, this threshold gave a sensitivity of 90.91% (95% CI: 70.84–98.88%), a specificity of
83.33% (95% CI: 35.88–99.58%), and an LR of 5.45, whereas the manufacturer’s threshold
of 1.4 gave a sensitivity of 77.27% (95% CI: 54.63–92.18%), a specificity of 83.3% (95%
CI: 35.88–99.58), and an LR of 4.64.
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new cut-off (sensitivity = 90.91% (95% CI: 70.84–98.88%), specificity = 83.33% (95% CI: 35.88–
99.58%)) and manufacturer’s cut-off (sensitivity = 77.27% (95% CI: 54.63–92.18%), specificity = 83.3% 
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22 RT-PCR-positive samples and 6 known RT-PCR-negative samples. Area under curve = 0.878, SE: 
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4. Discussion
SARS-CoV-2 serological assays have a pivotal role in assessing community transmis-
sion, especially in the evaluation of seroprevalence of both asymptomatic and symptomatic
cases. Based on several meta-analyses and epidemiological baseline modelling, around
30% of infected individuals display no symptoms [12], signifying a major source of asymp-
tomatic transmission. Thus, SARS-CoV-2 antibody tests could be used to define an accurate
extent of an outbreak and highlight its geographical distribution and hotspots. To achieve
this, serological assays need to confer enhanced sensitivity, where antibodies against the
SARS-CoV-2 nucleocapsid and Spike proteins can be detected, even at lower levels. Ab-
bott SARS-CoV-2 IgG immunoassay detects NC antibodies with claimed sensitivities of
98.3–100% [13–16]. However, the majority of these claims have been obtained from sam-
ples derived from patients hospitalised with severe COVID-19, who have high viral loads
and robust humoral responses. Here, we demonstrated that sensitivity of Abbott was
overestimated using the current manufacturer’s thresholds in a comparative evaluation
performed alongside TBS and Roche assays.
We collected serum samples from healthcare workers (HCWs) at two different sites
and evaluated the performance, with a focus on assay sensitivities, conferred by the
different SARS-CoV-2 antibody assays: TBS, Abbott and Roche. Samples from HCWs
were stratified according to the data available at each site. At Portsmouth University
Hospital (PHU), samples were stratified into positive and negative as reported by the
Abbott assay, and were later evaluated using the TBS assay. As samples from HCWs were
collected during the first wave, mass RT-PCR testing was not underway; thus, RT-PCR
ata wer not av ilable for most of these participants. Samples collected at DGH r
stratified into COVID-19-positive and -negative sampl s according to RT-PCR. At both
sites, concordance and agreement of SARS-CoV-2 serology were compared between the
different immunoassays.
Significant discrepancies were identified between the Abbott and TBS assays, with
only 66% co cordance found. Analysis of discrepa t samples using the Roche assay
showed perfe t agreement with the TBS assay, whilst only one result was concordant
bet en the Roche and Abbott assays. This hig lighted the potential for the significant
underestimation of seroprevalence using the Abbott assay. Of note, the sensitivity and
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specificity (97.4% and 80.0%, respectively) of the Abbott and Roche assays were identical
in samples tested at ≤58 days post-PCR or symptom onset, but differed significantly in
samples tested at >100 days post-PCR or symptom onset (77.3% by Abbot compared to
100% by Roche). As SARS-CoV-2 antibody levels naturally wane over time [17], this would
suggest that the Abbott assay lacks the sensitivity to detect lower antibody levels, which
can be detected using the Roche and TBS assays.
We hypothesised that the reasoning behind the lower sensitivity seen in Abbott was
primarily influenced by the high cut-off threshold set by the manufacturer. Such speculation
was supported by our findings, as using ROC analysis we defined a cut-off of 0.64, which
gave a sensitivity of 90.0% and showed good agreement with the Roche and TBS assay.
Whilst it does not meet the MHRA assay stipulation of 98% sensitivity and specificity [18],
the optimisation of this redefined threshold led to fewer false-negative results.
Our findings are supported by a recent study that used anosmia and ageusia reported
by HCWs as a high pre-test probability of mild and asymptomatic COVID-19 infections [17].
Correlation was observed between a high proportion of these reported anosmia/ageusia,
and increased antibody readings below the manufacturer’s thresholds. Adjustment for
reported anosmia and ageusia produced an estimated test sensitivity for the Abbott of
79.3%. It should be noted that this referred study uses self-reported symptoms of anosmia
and ageusia, which may be subjective. Furthermore, given the lack of a pre-COVID-19
group exposed to these same questions, there is some uncertainty in attributing these
symptoms uniquely to SARS-CoV-2 and not other respiratory viral illness.
Furthermore, the low sensitivity of the Abbott assay was also demonstrated in results
from the Spanish national serologic survey [19], which tested 5118 individuals with typical
COVID-19 symptoms within 14 days of symptom onset. It was found that only 18.0% of
these individuals had SARS-CoV-2 antibodies. The authors interpreted this as a “sizable
proportion of suspected cases might not have been caused by SARS-CoV-2”. We find this
explanation implausible and suggest that this data further supports our consensus that
the Abbott assay underestimates SARS-CoV-2 seroprevalence with the use of the current
manufacturer’s threshold. It is our opinion that the Abbott assay used in the Spanish study
conferred low sensitivity, which is supported by our findings of 77% sensitivity from our
data derived from two different hospital sites.
Another explanation for the seroprevalence underestimation observed in this Spanish
population could be due to the sampling time used in the study (14 days post-symptom
onset). Given the dynamics of humoral responses, 14 days post-viral challenge may not be
sufficient time to prompt an effective adaptive response. Thus, we recommend that any
future sero-epidemiological studies choose a sampling point post-symptom or PCR result
that enables apt time for the development of detectable antibodies.
Whilst sensitivity and specificity are crucial parameters for any serological assay,
estimating the PPV and NPV is useful when determining clinical and sero-epidemiological
utility. Our data demonstrate that Abbott’s low NPV (0.5) is not sufficient to rule out
an individual’s recent exposure to SARS-CoV-2, which calls into question the utility of
the assay when determining seroprevalence. As this study demonstrated, the TBS assay
demonstrated enhanced sensitivity, as it was able to detect low-level antibody responses.
This was supported by a recent study demonstrating that the TBS assay was able to detect
antibody responses in non-hospitalised asymptomatic COVID-19 patients and patients
with mild disease [9]. However, a significant proportion of these low-level antibody re-
sponses was not detected by Abbott assay when using the manufacturer’s cut-off threshold.
However, re-optimisation of a new cut-off level (0.64) significantly improved the sensitivity
of Abbott for detecting low-level antibody responses, which was comparable to both TBS
and Roche.
The current licenced COVID-19 vaccines target the Spike protein of SARS-CoV-2,
consequently eliciting humoral responses against the Spike protein. However, Roche
and Abbott assays both measure antibodies against the SARS-CoV-2 nucleocapsid pro-
tein; thus, they may not be of use in determining vaccination responses. Uniquely, the
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TBS assay detects SARS-CoV-2 antibodies against the trimeric spike protein, which is
the predominant immune response produced in response to SARS-CoV-2 vaccination. It
is our belief that the longitudinal measurement of antibody responses following vacci-
nation should be conducted using multiple assays that measure antibodies against the
spike protein, and that this should be done alongside frequent RT-PCR testing. Such
experimental design may allow the determination of protective antibody levels, as well as
cross-comparative evaluation of the performance of several anti-spike serological assays.
We envisage this as a multi-national study, analogous to the current SIREN study. Such
studies are urgently required.
Nevertheless, we believe nucleocapsid assays still have a role in sero-epidemiological
surveillance. We envisage dual serological testing from use of nucleocapsid and spike
assays. This will enable the identification of new seroconverts from natural infections
and the monitoring of vaccination responses in niche clinical scenarios, such as in poor
vaccine responders or the immunocompromised. It is paramount that proficient clinical
interpretation is available in sites utilising such diagnostic strategies. Moreover, we have
provided evidence here of the enhanced sensitivity of the TBS assay, which can be utilized
as a viable alternative that meets bespoke clinical and possible geographical needs where
high-throughput assays are unavailable on site.
The present study has some limitations. Firstly, our sample sets may under-represent
ethnic groups, did not comprise children, and did not capture sufficient clinical metadata
required for full clinical and analytical result interpretation. We propose a further study to
be conducted, where, along with the participant’s PCR status and clinical symptoms, the
investigation of these immunoassays to detect responses in asymptomatic and mild cases
should be evaluated to deduce the clinical sensitivity of different immunoassays. Whilst
limited, the study highlights that the TBS assay showed enhanced sensitivity in detecting
mild and asymptomatic antibody responses [9].
5. Conclusions
We demonstrate here that the Abbott manufacturer’s cut-off threshold leads to a
significant increase in false-negative outcomes, which contributes to the underestimation
of seroprevalence. The manufacturer’s cut-off at 1.4 overexaggerates the dynamics of
antibody waning, as seropositivity transitions into seronegative results much more quickly
in participants analysed by Abbott in comparison to Roche and TBS. Our findings provide
evidence that the Abbott manufacturer’s threshold should be redefined (0.64 index value),
which increases sensitivity (90%) and reduces the incidence of false negatives.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3
390/vaccines9111310/s1, Table S1: Summary of performance characterizes of each immunoassay as
provided by the manufacturer.
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